MDD Treatment Alternatives Explore Potential of Cannabis, Psychedelics
November 28th 2022Stemming from recent data on a potential link between major depressive disorder (MDD) and inflammation, research is starting to turn toward alternatives that can treat the disease through anti-inflammatory effects, including ketamine, cannabinoids, and psychedelics.
Read More
CBD May Improve Neurologic, Cognitive, QOL Outcomes in Sturge-Weber Syndrome
November 28th 2022A small, prospective, open-label trial found evidence of improved quality of life (QOL) and clinical outcomes among patients with treatment-resistant Sturge-Weber syndrome when they were treated with CBD.
Read More
Motor Function Continues to Improve in Second Year of Risdiplam Treatment for SMA
November 26th 2022Detailing findings from the secondary end points of the FIREFISH trial at 24 months, the researchers found that risdiplam treatment was associated with continued improvements in motor function and the achievement of development motor milestones.
Read More
Melissa O'Connor, PhD, MBA, RN, FGSA, FAAN, endowed professor in community and home health nursing, M. Louise Fitzpatrick School of Nursing, Villanova University, and director, Gerontology Interest Group, addressed barriers related to access, cost, and knowledge impeding technology use in home health.
Watch
Empagliflozin Has Similar Efficacy Across Subgroups, More Data Needed in CKD: Dr Jennifer Green
November 26th 2022Data on empagliflozin in chronic kidney disease (CKD) showed the drug had similar efficacy across subgroups, but more data is needed to really understand the benefit of the drug in CKD, said Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator.
Watch
Driving Biosimilar Uptake in Rheumatology, Biosimilar-to-Biosimilar Switching: ACR Abstracts
November 26th 2022Abstracts show that institutions can make internal changes to drive the use of biosimilars and that successful biosimilar-to-biosimilar switching is based on patient-related factors.
Read More
Dr Kevin Astle: Long-Acting Injectables Are a Game Changer for Adherence
November 26th 2022Now that long-acting injectables are approved, the next big concern is patient access, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.
Watch
FGFR Inhibitors Show Promise in Cholangiocarcinoma but Face Acquired Resistance
November 25th 2022There are currently 3 FDA-approved therapies to treat cholangiocarcinoma with FGFR2 fusion or rearrangement, but these therapies face the development of resistance. Studies are underway to identify ways to overcome this resistance.
Read More
Study Details Pandemic’s Depressive Effects in Older Adults
November 25th 2022It is well-known that depression generally, as well as the demand for mental health care, surged because of the pandemic, but few studies have identified the percentage of individuals who experienced depression for the first time after the pandemic began, or the percentage of those with a history of depression who saw it return.
Read More
Long-term Pioglitazone Use May Reduce Risk of Parkinson Disease in Patients With Diabetes
November 25th 2022Findings of a meta-analysis show that pioglitazone use with a dose duration greater than 438 days was associated with a significantly reduced risk of Parkinson disease in patients with diabetes.
Read More
Liz Lightstone, MBBS, PhD, FRCP, professor of renal medicine for the Faculty of Medicine, Imperial College London, discussed how the potential teratogenic effects of novel therapies being investigated for lupus nephritis can impede clinical trial recruitment for women of childbearing age.
Watch
T1D Index Will Be Updated Annually, JDRF’s Tom Robinson Explains
November 24th 2022Updating the Type 1 Diabetes (T1D) Index each year with the latest data and literature and implementing feedback is important for at least the first few years, said Tom Robinson, vice president of global access at JDRF.
Watch